Chugai Pharmaceutical Co Ltd (Chugai), a subsidiary of Roche Holding AG, specializes in biotechnological research and drug manufacturing. The company manufactures, markets, exports and imports pharmaceutical products in Japan and other countries. It provides drugs for cancer; renal diseases; transplants, immunology and infectious diseases and others therapy areas.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Chugai is actively engaged in research and development activities to create innovative medicines that address unmet medical needs. The company focuses on drug discovery from the patient's perspective, aiming to develop novel medicines that can be clearly differentiated and have a scientific basis for addressing unmet medical needs. Chugai is committed to utilizing proprietary technologies in various modalities, including small molecule drug discovery, next-generation antibodies, and macrocyclic peptide drug discovery. The company leverages AI technology to improve the probability of success in drug development, significantly reducing the time and cost of the drug discovery process. Chugai also emphasizes open innovation and strategic alliances, particularly with Roche, to enhance its R&D capabilities and accelerate the development of innovative drugs. Chugai has two core research laboratories in Japan: Chugai Life Science Park Yokohama and Ukima Research Laboratories. Chugai Life Science Park Yokohama serves as a base for drug discovery research, conducting activities from research on target molecules to preclinical development research. Ukima Research Laboratories focuses on late-stage development research, including pharmaceutical API manufacturing process research, product design, and quality testing methods. Additionally, Chugai Pharmabody Research Pte. Ltd. in Singapore utilizes Chugai's proprietary antibody engineering technologies to generate innovative therapeutic antibody candidates. The company has a robust R&D pipeline with projects in various stages of development, including oncology, hematological diseases, ophthalmology, and neurological diseases. Chugai has a strategic alliance with Roche, which provides exclusive rights to develop and market Roche products in Japan and allows Chugai's products to reach global markets. The company also collaborates with external partners, including academia and startup companies, to enhance its R&D capabilities. In FY2025, the company spent JPY185,657 million on its R&D activities, which as a percentage of revenue stood at 14.8% and grew 5% YoY.